Atossa Therapeutics, Inc. has announced plans for a new Phase 3 clinical trial, SMART 2.0, which will explore the effectiveness of oral (Z)-endoxifen in reducing interval breast cancer among high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback